Related Experiment Video
Updated: May 13, 2026

Genome-wide Analysis using ChIP to Identify Isoform-specific Gene Targets
Published on: July 7, 2010
The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia
Maria Francisca Arteaga1, Jan-Henrik Mikesch, Jihui Qiu
1Leukaemia and Stem Cell Biology Group, Department of Haematological Medicine, King's College London, Denmark Hill, London SE5 9NU, UK.
Abstract:
While all-trans retinoic acid (ATRA) treatment in acute promyelocytic leukemia (APL) has been the paradigm of targeted therapy for oncogenic transcription factors, the underlying mechanisms remain largely unknown, and a significant number of patients still relapse and become ATRA resistant. We identified the histone demethylase PHF8 as a coactivator that is specifically recruited by RARα fusions to activate expression of their downstream targets upon ATRA treatment. Forced expression of PHF8 resensitizes ATRA-resistant APL cells, whereas its downregulation confers resistance. ATRA sensitivity depends on the enzymatic activity and phosphorylation status of PHF8, which can be pharmacologically manipulated to resurrect ATRA sensitivity to resistant cells. These findings provide important molecular insights into ATRA response and a promising avenue for overcoming ATRA resistance.
Insights
Researchers found that the histone demethylase PHF8 is crucial for all-trans retinoic acid (ATRA) effectiveness in acute promyelocytic leukemia (APL). Manipulating PHF8 activity can overcome ATRA resistance in APL patients.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- All-trans retinoic acid (ATRA) is a cornerstone therapy for acute promyelocytic leukemia (APL), targeting oncogenic transcription factors.
- Mechanisms of ATRA action are not fully understood, and ATRA resistance remains a clinical challenge, leading to patient relapse.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying ATRA response and resistance in APL.
- To identify novel therapeutic targets for overcoming ATRA resistance in APL.
Main Methods:
- Investigated the role of histone demethylase PHF8 in ATRA-treated APL cells.
- Assessed the impact of PHF8 expression and enzymatic activity on ATRA sensitivity.
- Explored pharmacological manipulation of PHF8 to restore ATRA sensitivity in resistant cells.
Main Results:
- PHF8 acts as a coactivator, recruited by RARα fusions to enhance target gene expression upon ATRA treatment.
- Forced PHF8 expression resensitizes ATRA-resistant APL cells; PHF8 downregulation induces resistance.
- ATRA sensitivity is contingent on PHF8's enzymatic activity and phosphorylation state.
Conclusions:
- PHF8 is a key mediator of ATRA sensitivity in APL.
- Pharmacological targeting of PHF8 activity presents a promising strategy to overcome ATRA resistance and improve APL treatment outcomes.
Related Concept Videos
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation

